Boston Scientific Pushes Forward Despite $200M Tariff Challenge
Boston Scientific has announced that tariffs are expected to add approximately $200 million to its costs this year, but the company remains confident in its ability to absorb the financial hit. Despite the tariff burden, the company reported robust growth across its cardiology and urology divisions, reflecting strong overall performance.
In its Q1 2025 earnings report, the company posted total sales of $4.66 billion, a 22.2% increase from the previous year. Significant contributions came from its medical-surgical division, which saw urology net sales rise by 24.5%, partly driven by its kidney stone ...
